Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.
French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.
WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.
Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity.
Ovation.io reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.
The committee spoke out against clinical applications of human germline genome editing and called for stronger global governance of the field.
Canvassing more than 400,000 people in 8 months, Apple has finished an investigation of its smartwatch’s ability to detect irregular heart rhythms.
ExcepGen believes its approach could speed up discovery and even come up with protein targets previously thought to be undruggable.
Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.
Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.